
FDA Approves Obinutuzumab as First Therapy for Membranous Nephropathy
Key Takeaways
- FDA approval establishes obinutuzumab as the first on-label option for PMN, a rare autoimmune nephropathy with ~30% untreated progression to kidney failure at 10 years.
- MAJESTY randomized 142 adults to IV obinutuzumab versus oral tacrolimus for 104 weeks in an open-label, multicenter phase 3 design.
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
Obinutuzumab (Gazyva; Genentech) is now the first drug approved specifically to treat adults with primary membranous nephropathy (PMN), with an indication to induce remission of proteinuria in patients at risk of disease progression.1
The anti-CD20 monoclonal antibody was previously approved for certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome. Its PMN application received breakthrough therapy, orphan drug, and priority review designations.
A Rare Autoimmune Kidney Disease Gets Its First Approved Treatment
PMN is a rare disease in which the immune system attacks the glomeruli, the filtering units of the
Up to 30% of untreated patients progress to kidney failure within 10 years, and the estimated incidence in the US is 1.2 per 100,000 people per year, Genentech said when the FDA granted the application priority review in July.2 The agency had granted Breakthrough Therapy designation in April 2026.
“This priority review represents an important step for patients living with primary membranous nephropathy, a chronic disease with no FDA-approved treatments," said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, Genentech,
Without an approved option, clinicians have turned to therapies used off label. One of those, tacrolimus, served as the comparator in the trial that supported the approval.
36% Reached Complete Remission With Obinutuzumab vs 6% With Tacrolimus
The approval rests on MAJESTY (
The primary end point was complete remission of proteinuria, defined as a urine protein-creatinine ratio of no more than 0.3 g/g with stable estimated glomerular filtration rate at week 104, without rescue therapy, treatment failure, or early discontinuation. At week 104, 36% of patients in the obinutuzumab group met that definition, compared with 6% of patients in the tacrolimus group.
Obinutuzumab was also superior to tacrolimus on 2 key secondary end points, overall remission (complete or partial) at week 104 and complete remission at week 76, according to Genentech.2 The company described MAJESTY as the fourth positive phase 3 study of obinutuzumab in immune-mediated diseases, following REGENCY (
Full trial results, presented at the 63rd European Renal Association Congress and published in June in the
Boxed Warning Covers Hepatitis B Reactivation and PML
Obinutuzumab's label carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy, a rare, serious brain infection.1 The most common adverse reactions among patients with PMN in the trial were infusion-related reactions and upper respiratory tract infection.
In the published report, the investigators listed infusion-related reactions, respiratory tract infections, and neutropenia among the adverse drug reactions seen with obinutuzumab.3 They framed the trial as a needed test of the type II anti-CD20 antibody in PMN, noting that earlier studies had shown its efficacy in hematologic cancers and autoimmune diseases.
References
- FDA approves first drug to treat adults with primary membranous nephropathy. FDA. November 13, 2026. Accessed November 18, 2026.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy - FDA grants priority review to Genentech's Gazyva for adults with primary membranous nephropathy. News release. Genentech. July 14, 2026. Accessed November 18, 2026.
https://www.gene.com/media/press-releases/15121/2026-07-14/fda-grants-priority-review-to-genentechs - Fervenza FC, Hou FF, Hao CM, et al. Obinutuzumab or tacrolimus in primary membranous nephropathy. N Engl J Med. 2026;395(10):959-971. doi:10.1056/NEJMoa2602678
Related to this article








